By: Chris Ryan From: onclive.com The FDA has approved vepdegestrant (Veppanu) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least 1 line of endocrine therapy.1,2 The approval was backed by data from the phase 3 VERITAC-2 trial (NCT05654623), which demonstrated …
Vepdegestrant Demonstrates Progression-Free Survival in Patients With ER+/HER2- Metastatic Breast Cancer
From: pharmacytimes.com Vepdegestrant (ARV-471; Arvinas, Inc) met its primary end point of progression-free survival (PFS) compared with fulvestrant (Faslodex; AstraZeneca) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with CDK 4/6 inhibitors and endocrine therapy. The clinically meaningful outcomes were observed in the phase …
No Added Benefit From Chemo in This Breast Cancer Subtype
By: Liam Davenport From: medscape.com TOPLINE: Women with estrogen receptor (ER)–positive, human epidermal growth factor receptor 2 (HER2)–negative invasive lobular carcinoma who are treated with endocrine therapy do not derive any additional survival benefit from neoadjuvant or adjuvant chemotherapy. METHODOLOGY: Studies evaluating the long-term effects of chemotherapy in patients with invasive lobular carcinoma are limited and often “show inconclusive results,” …
Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2- Breast Cancer
By: Ashling Wahner From: onclive.com Neoadjuvant pembrolizumab (Keytruda) plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response (pCR) vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor (ER)–positive, HER2-negative breast cancer, according to data from the phase 3 KEYNOTE-756 trial (NCT03725059) …
Z-endoxifen Combination Therapy Commences in Patients With ER+/HER2– Breast Cancer
By: Nichole Tucker From: targetedonc.com Treatment with (Z)-endoxifen in combination with exemestane plus goserelin in the phase 2 EVANGELINE is now underway In a patient with estrogen receptor (ER)-positive, HER2-negative breast cancer, neoadjuvant treatment with (Z)-endoxifen in combination with exemestane plus goserelin has been dosed for the first time, signaling the start of the phase 2 EVANGELINE (NCT05607004) trial.1 The …
FDA Grants Fast Track Designation to CFI-402257 for ER+/HER2– Breast Cancer
By: Chris Ryan From: onclive.com The FDA has granted a fast track designation to best-in-class threonine tyrosine kinase (TTK) inhibitor CFI-402257, both as monotherapy and in combination with fulvestrant (Faslodex), for the treatment of adult patients with estrogen receptor (ER)–positive/HER2-negative advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy.1 TTK, which is correlated with high grade …
Updated results on a new approach to treating advanced ER-positive/HER2-negative breast cancer
Source: University of California – Los Angeles Health Sciences From: news-medical.net A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer. The study is the first-in-human, open-label, three-part study of ARV-471, alone or in combination with the drug …
AMEERA-1 and ER+/HER2- Metastatic Breast Cancer
By: Sarat Chandarlapaty, MD, PhD From: targetedonc.com Sarat Chandarlapaty, MD, offers his opinion on the potential roles amcenestrant could have in the treatment of ER+/HER2- metastatic breast cancer. Sarat Chandarlapaty, MD: The potential roles for amcenestrant could be a replacement of every place we use antiestrogen therapy in breast cancer. There’s potential for replacement of aromatase inhibitors, in the neoadjuvant …
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy of Oral Lasofoxifene Versus Intramuscular Fulvestrant
Source: Sermonix Pharmaceuticals LLC From: globenewswire.com The study enrolled 100 patients who have ER+/HER2- breast cancer with an ESR1 mutation, with topline data expected in first half of 2022 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it has completed enrollment in its Phase 2 randomized …
Examining resistance to breast cancer treatments
By: Molly Chiu From: bcm.edu The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester …